ABI
ALNY icon

Adamant Biomedical Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Adamant Biomedical Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$2.23M Hold
23,000
– – 0.53% 61
2014
Q3 		$1.8M Buy
+23,000
New +$1.48M 0.45% 63

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Adamant Biomedical Investments's ALNY Position: Q4 2014 in Review

Adamant Biomedical Investments held its Alnylam Pharmaceuticals (ALNY) position steady in Q4 2014 at 23,000 shares worth $2.23M. The position accounts for 0.53% of the portfolio, ranked #61.

Adamant Biomedical Investments first reported a position in ALNY in Q3 2014 and has held it in 2 quarters since. 216 funds tracked by Wall St. Rank hold ALNY as of Q4 2014.

  • Adamant Biomedical Investments held 23,000 shares of Alnylam Pharmaceuticals worth $2.23M as of Q4 2014.
  • Adamant Biomedical Investments left its Alnylam Pharmaceuticals share count unchanged in Q4 2014.
  • Alnylam Pharmaceuticals made up 0.53% of Adamant Biomedical Investments's portfolio in Q4 2014, its #61 holding.
  • Adamant Biomedical Investments first reported a position in Alnylam Pharmaceuticals in Q3 2014 and has held it in 2 quarters since.
  • 216 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.